Adrian Preda

List of Publications by Year in Descending Order

199 papers	14,637 citations	62 h-index	118 g-index
242 ext. papers	17,930 ext. citations	5.5 avg, IF	6.1 L-index

#	Paper	IF	Citations
199	Building Models of Functional Interactions Among Brain Domains that Encode Varying Information Complexity: A Schizophrenia Case Study.. *Neuroinformatics*, **2022**, 1	3.2	
198	Moving Beyond the 'CAP' of the Iceberg: Intrinsic Connectivity Networks in fMRI are Continuously Engaging and Overlapping.. *NeuroImage*, **2022**, 119013	7.9	1
197	ENIGMA + COINSTAC: Improving Findability, Accessibility, Interoperability, and Re-usability. *Neuroinformatics*, **2021**, 1	3.2	
196	Aberrant Dynamic Functional Connectivity of Default Mode Network in Schizophrenia and Links to Symptom Severity. *Frontiers in Neural Circuits*, **2021**, 15, 649417	3.5	4
195	Brain Density Clustering Analysis: A New Approach to Brain Functional Dynamics. *Frontiers in Neuroscience*, **2021**, 15, 621716	5.1	0
194	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. *JAMA Psychiatry*, **2021**, 78, 47-63	14.5	43
193	Multiple overlapping dynamic patterns of the visual sensory network in schizophrenia. *Schizophrenia Research*, **2021**, 228, 103-111	3.6	3
192	A meta-analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA Consortium. *Human Brain Mapping*, **2021**,	5.9	7
191	Multimodel Order Independent Component Analysis: A Data-Driven Method for Evaluating Brain Functional Network Connectivity Within and Between Multiple Spatial Scales. *Brain Connectivity*, **2021**,	2.7	1
190	Reward Processing in Novelty Seekers: A Transdiagnostic Psychiatric Imaging Biomarker. *Biological Psychiatry*, **2021**, 90, 529-539	7.9	5
189	Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy. *Psychiatry Research*, **2021**, 305, 114199	9.9	0
188	Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA. *NeuroImage*, **2020**, 218, 116956	7.9	32
187	The genetic architecture of the human cerebral cortex. *Science*, **2020**, 367,	33.3	156
186	Covarying structural alterations in laterality of the temporal lobe in schizophrenia: A case for source-based laterality. *NMR in Biomedicine*, **2020**, 33, e4294	4.4	1
185	Meta-Modal Information Flow: A Method for Capturing Multimodal Modular Disconnectivity in Schizophrenia. *IEEE Transactions on Biomedical Engineering*, **2020**, 67, 2572-2584	5	4
184	Weighted average of shared trajectory: A new estimator for dynamic functional connectivity efficiently estimates both rapid and slow changes over time. *Journal of Neuroscience Methods*, **2020** , 334, 108600	3	12
183	A safety evaluation of aripiprazole in the treatment of schizophrenia. *Expert Opinion on Drug Safety*, **2020**, 19, 1529-1538	4.1	10

182	Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial. *Schizophrenia Bulletin*, **2020**, 46, 661-669	1.3	6
181	A Homolog for Dementia Case Finding with Replication in the Alzheimer's Disease Neuroimaging Initiative. *Journal of Alzheimer's Disease*, **2019**, 67, 67-79	4.3	6
180	Parallel group ICA+ICA: Joint estimation of linked functional network variability and structural covariation with application to schizophrenia. *Human Brain Mapping*, **2019**, 40, 3795-3809	5.9	16
179	Autoconnectivity: A new perspective on human brain function. *Journal of Neuroscience Methods*, **2019**, 323, 68-76	3	5
178	A Review of Statistical Methods in Imaging Genetics. *Canadian Journal of Statistics*, **2019**, 47, 108-131	0.4	12
177	The spatial chronnectome reveals a dynamic interplay between functional segregation and integration. *Human Brain Mapping*, **2019**, 40, 3058-3077	5.9	32
176	Longitudinal Brain Atrophy Rates in Transient Ischemic Attack and Minor Ischemic Stroke Patients and Cognitive Profiles. *Frontiers in Neurology*, **2019**, 10, 18	4.1	8
175	Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3. *Frontiers in Neuroinformatics*, **2019**, 13, 2	3.9	33
174	A method for building a genome-connectome bipartite graph model. *Journal of Neuroscience Methods*, **2019**, 320, 64-71	3	0
173	A blood-based signature of cerebrospinal fluid A status. *Scientific Reports*, **2019**, 9, 4163	4.9	15
172	Random forest prediction of Alzheimer's disease using pairwise selection from time series data. *PLoS ONE*, **2019**, 14, e0211558	3.7	42
171	Longitudinal Functional Brain Mapping in Supernormals. *Cerebral Cortex*, **2019**, 29, 242-252	5.1	14
170	A Novel Method to Estimate Long-Term Chronological Changes From Fragmented Observations in Disease Progression. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 436-447	6.1	3
169	Communicability disruption in Alzheimer disease connectivity networks. *Journal of Complex Networks*, **2019**, 7, 83-100	1.7	20
168	Characterizing Whole Brain Temporal Variation of Functional Connectivity via Zero and First Order Derivatives of Sliding Window Correlations. *Frontiers in Neuroscience*, **2019**, 13, 634	5.1	12
167	Robust Motion Regression of Resting-State Data Using a Convolutional Neural Network Model. *Frontiers in Neuroscience*, **2019**, 13, 169	5.1	8
166	Altered Domain Functional Network Connectivity Strength and Randomness in Schizophrenia. *Frontiers in Psychiatry*, **2019**, 10, 499	5	3
165	rs242557 variant is associated with hippocampus tau uptake on F-AV-1451 PET in non-demented elders. *Aging*, **2019**, 11, 874-884	5.6	5

164	Evaluating trajectories of episodic memory in normal cognition and mild cognitive impairment: Results from ADNI. *PLoS ONE*, **2019**, 14, e0212435	3.7	12
163	Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics. *Scientific Reports*, **2019**, 9, 2235	4.9	24
162	Predicting Alzheimer's disease progression using multi-modal deep learning approach. *Scientific Reports*, **2019**, 9, 1952	4.9	88
161	Salience-Default Mode Functional Network Connectivity Linked to Positive and Negative Symptoms of Schizophrenia. *Schizophrenia Bulletin*, **2019**, 45, 892-901	1.3	32
160	Cortical thickness atrophy in the transentorhinal cortex in mild cognitive impairment. *NeuroImage: Clinical*, **2019**, 21, 101617	5.3	22
159	Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data. *NeuroImage: Clinical*, **2019**, 21, 101637	5.3	15
158	Spatial dynamics within and between brain functional domains: A hierarchical approach to study time-varying brain function. *Human Brain Mapping*, **2019**, 40, 1969-1986	5.9	27
157	A concise and persistent feature to study brain resting-state network dynamics: Findings from the Alzheimer's Disease Neuroimaging Initiative. *Human Brain Mapping*, **2019**, 40, 1062-1081	5.9	14
156	White matter in different regions evolves differently during progression to dementia. *Neurobiology of Aging*, **2019**, 76, 71-79	5.6	16
155	QuickNAT: A fully convolutional network for quick and accurate segmentation of neuroanatomy. *NeuroImage*, **2019**, 186, 713-727	7.9	90
154	Association of CSF CD40 levels and synaptic degeneration across the Alzheimer's disease spectrum. *Neuroscience Letters*, **2019**, 694, 41-45	3.3	5
153	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. *Biological Psychiatry*, **2019**, 85, e35-e39	7.9	4
152	Disease progression timeline estimation for Alzheimer's disease using discriminative event based modeling. *NeuroImage*, **2019**, 186, 518-532	7.9	32
151	Translating Alzheimer's disease-associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs. *Neurobiology of Aging*, **2019**, 74, 135-146	5.6	16
150	Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. *Alzheimer's and Dementia*, **2019**, 15, 194-204	1.2	31
149	Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 334-347	8.8	14
148	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. *Alzheimer's and Dementia*, **2019**, 15, 106-152	1.2	153
147	Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome. *Alzheimer's and Dementia*, **2019**, 15, 76-92	1.2	208

146	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. *Alzheimer's and Dementia*, **2019**, 15, 232-244	1.2	95
145	Amyloid beta-positive subjects exhibit longitudinal network-specific reductions in spontaneous brain activity. *Neurobiology of Aging*, **2019**, 74, 191-201	5.6	5
144	Next Generation Sequencing Analysis in Early Onset Dementia Patients. *Journal of Alzheimer's Disease*, **2019**, 67, 243-256	4.3	20
143	Functional signature of conversion of patients with mild cognitive impairment. *Neurobiology of Aging*, **2019**, 74, 21-37	5.6	20
142	A framework for linking resting-state chronnectome/genome features in schizophrenia: A pilot study. *NeuroImage*, **2019**, 184, 843-854	7.9	12
141	Dual-Model Radiomic Biomarkers Predict Development of Mild Cognitive Impairment Progression to Alzheimer's Disease. *Frontiers in Neuroscience*, **2018**, 12, 1045	5.1	26
140	Resting-state thalamic dysconnectivity in schizophrenia and relationships with symptoms. *Psychological Medicine*, **2018**, 48, 2492-2499	6.9	42
139	Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia. *Schizophrenia Research*, **2018**, 199, 226-234	3.6	18
138	Decreased hemispheric connectivity and decreased intra- and inter- hemisphere asymmetry of resting state functional network connectivity in schizophrenia. *Brain Imaging and Behavior*, **2018**, 12, 615-630	4.1	17
137	Multimodal Fusion With Reference: Searching for Joint Neuromarkers of Working Memory Deficits in Schizophrenia. *IEEE Transactions on Medical Imaging*, **2018**, 37, 93-105	11.7	35
136	Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group. *Molecular Psychiatry*, **2018**, 23, 1261-1269	15.1	324
135	Multimodal neuromarkers in schizophrenia via cognition-guided MRI fusion. *Nature Communications* , **2018**, 9, 3028	17.4	71
134	INTEGRATING SEMI-SUPERVISED LABEL PROPAGATION AND RANDOM FORESTS FOR MULTI-ATLAS BASED HIPPOCAMPUS SEGMENTATION **2018**, 2018, 154-157	1.5	10
133	Medical Image Imputation from Image Collections. *IEEE Transactions on Medical Imaging*, **2018**,	11.7	23
132	Fast Multi-Task SCCA Learning with Feature Selection for Multi-Modal Brain Imaging Genetics **2018**, 2018, 356-361	0.8	7
131	Predicting progressions of cognitive outcomes via high-order multi-modal multi-task feature learning **2018**,		3
130	Multiple incomplete views clustering via non-negative matrix factorization with its application in Alzheimer's disease analysis **2018**,		2
129	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. *Biological Psychiatry*, **2018**, 84, 644-654	7.9	325

128	A positive take on schizophrenia negative symptom scales: Converting scores between the SANS, NSA and SDS. *Schizophrenia Research*, **2018**, 201, 113-119	3.6	3
127	Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium. *Acta Psychiatrica Scandinavica*, **2017**, 135, 439-447	6.5	47
126	Modality-Dependent Impact of Hallucinations on Low-Frequency Fluctuations in Schizophrenia. *Schizophrenia Bulletin*, **2017**, 43, 389-396	1.3	26
125	The Function Biomedical Informatics Research Network Data Repository. *NeuroImage*, **2016**, 124, 1074-1079	7.9	53
124	Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Molecular Psychiatry*, **2016**, 21, 547-53	15.1	525
123	Supervised multimodal fusion and its application in searching joint neuromarkers of working memory deficits in schizophrenia. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2016**, 2016, 4024-4026	0.9	3
122	Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 395-407	4	11
121	Higher Dimensional Meta-State Analysis Reveals Reduced Resting fMRI Connectivity Dynamism in Schizophrenia Patients. *PLoS ONE*, **2016**, 11, e0149849	3.7	98
120	Relating Intrinsic Low-Frequency BOLD Cortical Oscillations to Cognition in Schizophrenia. *Neuropsychopharmacology*, **2015**, 40, 2705-14	8.7	46
119	Visual hallucinations are associated with hyperconnectivity between the amygdala and visual cortex in people with a diagnosis of schizophrenia. *Schizophrenia Bulletin*, **2015**, 41, 223-32	1.3	88
118	Neural Correlates of Schizophrenia Negative Symptoms: Distinct Subtypes Impact Dissociable Brain Circuits. *Molecular Neuropsychiatry*, **2015**, 1, 191-200	4.9	31
117	Functional magnetic resonance imaging of motor cortex activation in schizophrenia. *Journal of Korean Medical Science*, **2015**, 30, 625-31	4.7	2
116	Multidimensional frequency domain analysis of full-volume fMRI reveals significant effects of age, gender, and mental illness on the spatiotemporal organization of resting-state brain activity. *Frontiers in Neuroscience*, **2015**, 9, 203	5.1	7
115	Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. *Nature Communications*, **2015**, 6, 6760	17.4	167
114	Neuropsychological profile in adult schizophrenia measured with the CMINDS. *Psychiatry Research*, **2015**, 230, 826-34	9.9	25
113	Quality Assurance in Functional MRI. *Biological Magnetic Resonance*, **2015**, 245-270	0.5	4
112	Schizophrenia miR-137 locus risk genotype is associated with dorsolateral prefrontal cortex hyperactivation. *Biological Psychiatry*, **2014**, 75, 398-405	7.9	59
111	Impact of autocorrelation on functional connectivity. *NeuroImage*, **2014**, 102 Pt 2, 294-308	7.9	67

110	Dynamic functional connectivity analysis reveals transient states of dysconnectivity in schizophrenia. *NeuroImage: Clinical*, **2014**, 5, 298-308	5.3	608
109	D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. *CNS Spectrums*, **2014**, 19, 176-81	1.8	16
108	Predictive factors for natural pregnancy after microsurgical reconstruction in patients with primary epididymal obstructive azoospermia. *International Journal of Endocrinology*, **2014**, 2014, 873527	2.7	6
107	A multi-scanner study of subcortical brain volume abnormalities in schizophrenia. *Psychiatry Research - Neuroimaging*, **2014**, 222, 10-6	2.9	30
106	Converting positive and negative symptom scores between PANSS and SAPS/SANS. *Schizophrenia Research*, **2014**, 152, 289-94	3.6	79
105	Informed consent: how much awareness is there?. *PLoS ONE*, **2014**, 9, e110139	3.7	26
104	Brain Imaging Correlates of Anhedonia **2014**, 331-341		1
103	Improved inference in Bayesian segmentation using Monte Carlo sampling: application to hippocampal subfield volumetry. *Medical Image Analysis*, **2013**, 17, 766-78	15.4	33
102	Semi-supervised multimodal relevance vector regression improves cognitive performance estimation from imaging and biological biomarkers. *Neuroinformatics*, **2013**, 11, 339-53	3.2	18
101	The receiver operational characteristic for binary classification with multiple indices and its application to the neuroimaging study of Alzheimer's disease. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, **2013**, 10, 173-80	3	19
100	Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 4768-73	11.5	123
99	Predicting brain activity using a Bayesian spatial model. *Statistical Methods in Medical Research*, **2013**, 22, 382-97	2.3	17
98	Standardization of analysis sets for reporting results from ADNI MRI data. *Alzheimer's and Dementia* , **2013**, 9, 332-7	1.2	129
97	Functional activity maps based on significance measures and Independent Component Analysis. *Computer Methods and Programs in Biomedicine*, **2013**, 111, 255-68	6.9	19
96	GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. *Neuron*, **2013**, 78, 256-68	13.9	255
95	Segmentation of MR images via discriminative dictionary learning and sparse coding: application to hippocampus labeling. *NeuroImage*, **2013**, 76, 11-23	7.9	168
94	Brain changes in older adults at very low risk for Alzheimer's disease. *Journal of Neuroscience*, **2013**, 33, 8237-42	6.6	152
93	Predicting the location of human perirhinal cortex, Brodmann's area 35, from MRI. *NeuroImage*, **2013**, 64, 32-42	7.9	59

92	Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning. *NeuroImage*, **2013**, 65, 511-21	7.9	176
91	Man versus machine: comparison of radiologists' interpretations and NeuroQuant® volumetric analyses of brain MRIs in patients with traumatic brain injury. *Journal of Neuropsychiatry and Clinical Neurosciences*, **2013**, 25, 32-9	2.7	36
90	Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease. *PLoS Computational Biology*, **2013**, 9, e1002987	5	56
89	Fat-mass-related hormone, plasma leptin, predicts brain volumes in the elderly. *NeuroReport*, **2013**, 24, 58-62	1.7	36
88	ACP Journal Club. Review: antipsychotic drugs improve symptoms, with different levels of side effects, in schizophrenia. *Annals of Internal Medicine*, **2013**, 159, JC7	8	2
87	Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool. *PLoS ONE*, **2013**, 8, e55246	3.7	28
86	aBEAT: a toolbox for consistent analysis of longitudinal adult brain MRI. *PLoS ONE*, **2013**, 8, e60344	3.7	7
85	Design and application of a generic clinical decision support system for multiscale data. *IEEE Transactions on Biomedical Engineering*, **2012**, 59, 234-40	5	34
84	Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. *NeuroImage*, **2012**, 61, 622-32	7.9	127
83	Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. *Archives of Neurology*, **2012**, 69, 1310-7		142
82	Fast identification of biological pathways associated with a quantitative trait using group lasso with overlaps. *Statistical Applications in Genetics and Molecular Biology*, **2012**, 11, Article 7	1.2	36
81	Blood-based protein biomarkers for diagnosis of Alzheimer disease. *Archives of Neurology*, **2012**, 69, 1318-25		271
80	MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. *Neurology*, **2012**, 78, 84-90	6.5	145
79	Identification of common variants associated with human hippocampal and intracranial volumes. *Nature Genetics*, **2012**, 44, 552-61	36.3	498
78	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 1599-608	5.6	38
77	Empirical derivation of the reference region for computing diagnostic sensitive □fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2012**, 1822, 457-66	6.9	16
76	Does feature selection improve classification accuracy? Impact of sample size and feature selection on classification using anatomical magnetic resonance images. *NeuroImage*, **2012**, 60, 59-70	7.9	220
75	Naming impairment in Alzheimer's disease is associated with left anterior temporal lobe atrophy. *NeuroImage*, **2012**, 63, 348-55	7.9	72

74	Longitudinal change in neuropsychological performance using latent growth models: a study of mild cognitive impairment. *Brain Imaging and Behavior*, **2012**, 6, 540-50	4.1	43
73	The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. *Brain Imaging and Behavior*, **2012**, 6, 489-501	4.1	85
72	CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. *Brain Imaging and Behavior*, **2012**, 6, 599-609	4.1	37
71	A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. *Brain Imaging and Behavior*, **2012**, 6, 517-27	4.1	265
70	Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease. *Brain Imaging and Behavior*, **2012**, 6, 610-20	4.1	46
69	Cortical signatures of cognition and their relationship to Alzheimer's disease. *Brain Imaging and Behavior*, **2012**, 6, 584-98	4.1	19
68	Genetic architecture of resilience of executive functioning. *Brain Imaging and Behavior*, **2012**, 6, 621-33	4.1	18
67	Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Brain Imaging and Behavior*, **2012**, 6, 502-16	4.1	303
66	Confirmatory factor analysis of the ADNI Neuropsychological Battery. *Brain Imaging and Behavior*, **2012**, 6, 528-39	4.1	40
65	Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. *Brain Imaging and Behavior*, **2012**, 6, 634-48	4.1	55
64	Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. *Brain Imaging and Behavior*, **2012**, 6, 551-67	4.1	50
63	Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI. *Brain Imaging and Behavior*, **2012**, 6, 649-60	4.1	10
62	Relationship between baseline brain metabolism measured using [□F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. *Brain Imaging and Behavior*, **2012**, 6, 568-83	4.1	40
61	Improved classification of Alzheimer's disease data via removal of nuisance variability. *PLoS ONE*, **2012**, 7, e31112	3.7	35
60	Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. *PLoS ONE*, **2012**, 7, e34341	3.7	58
59	Rates of decline in Alzheimer disease decrease with age. *PLoS ONE*, **2012**, 7, e42325	3.7	72
58	Plasma based markers of [11C] PiB-PET brain amyloid burden. *PLoS ONE*, **2012**, 7, e44260	3.7	64
57	Analysis of copy number variation in Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. *PLoS ONE*, **2012**, 7, e50640	3.7	35

56	Structural brain alterations before mild cognitive impairment in ADNI: validation of volume loss in a predefined antero-temporal region. *Journal of Alzheimer's Disease*, **2012**, 31 Suppl 3, S49-58	4.3	20
55	Amyloid-□associated clinical decline occurs only in the presence of elevated P-tau. *Archives of Neurology*, **2012**, 69, 709-13		103
54	Function biomedical informatics research network recommendations for prospective multicenter functional MRI studies. *Journal of Magnetic Resonance Imaging*, **2012**, 36, 39-54	5.6	171
53	Vascular burden and Alzheimer disease pathologic progression. *Neurology*, **2012**, 79, 1349-55	6.5	121
52	Predicting missing biomarker data in a longitudinal study of Alzheimer disease. *Neurology*, **2012**, 78, 1376-82	6.5	25
51	Identifying disease sensitive and quantitative trait-relevant biomarkers from multidimensional heterogeneous imaging genetics data via sparse multimodal multitask learning. *Bioinformatics*, **2012**, 28, i127-36	7.2	90
50	Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 3985-90	11.5	43
49	Gender modulates the APOE □4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. *Journal of Neuroscience*, **2012**, 32, 8254-62	6.6	176
48	Classification of structural MRI images in Alzheimer's disease from the perspective of ill-posed problems. *PLoS ONE*, **2012**, 7, e44877	3.7	32
47	Genetic variants in the Fat and Obesity Associated (FTO) gene and risk of Alzheimer's disease. *PLoS ONE*, **2012**, 7, e50354	3.7	73
46	Alzheimer disease biomarkers are associated with body mass index. *Neurology*, **2011**, 77, 1913-20	6.5	85
45	The self and Asperger syndrome. *Southern Medical Journal*, **2011**, 104, 250-1	0.6	
44	Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. *PLoS ONE*, **2011**, 6, e25446	3.7	204
43	Longitudinal Course of Schizophrenia. *Current Psychiatry Reviews*, **2011**, 7, 205-216	0.9	1
42	The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. *Journal of Psychiatric Research*, **2011**, 45, 64-75	5.2	34
41	Predicting MCI outcome with clinically available MRI and CSF biomarkers. *Neurology*, **2011**, 77, 1619-28	6.5	160
40	Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. *Radiology*, **2011**, 259, 844-51	20.5	38
39	Longitudinal change of biomarkers in cognitive decline. *Archives of Neurology*, **2011**, 68, 1257-66		130

38	Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. *Neurology*, **2011**, 76, 69-79	6.5	150
37	Course of Schizophrenia: What Has Been Learned from Longitudinal Studies? **2011**, 281-300		1
36	Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia **2011**, 33-74		1
35	A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 8404-9	11.5	202
34	Sex-dependent association of common variants of microcephaly genes with brain structure. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 384-8	11.5	111
33	A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). *NeuroImage*, **2010**, 50, 1427-37	7.9	96
32	Voxelwise genome-wide association study (vGWAS). *NeuroImage*, **2010**, 53, 1160-74	7.9	197
31	Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. *NeuroImage*, **2010**, 53, 1147-59	7.9	154
30	Multi-modal imaging predicts memory performance in normal aging and cognitive decline. *Neurobiology of Aging*, **2010**, 31, 1107-21	5.6	125
29	Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. *Neurobiology of Aging*, **2010**, 31, 1452-62, 1462.e1-2	5.6	61
28	Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. *NeuroImage*, **2010**, 53, 1051-63	7.9	266
27	Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 10256-61	11.5	172
26	Bypassing shame and conversion disorder. *CNS Spectrums*, **2010**, 15, 607-11	1.8	2
25	Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease. *NeuroReport*, **2010**, 21, 802-7	1.7	18
24	Using new antipsychotics in your clinical practice. *Journal of Clinical Psychiatry*, **2010**, 71, e101	4.6	
23	Tuning in to the voices: a multisite FMRI study of auditory hallucinations. *Schizophrenia Bulletin*, **2009**, 35, 58-66	1.3	91
22	Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. *Brain*, **2009**, 132, 1310-23	11.2	526
21	Subregional neuroanatomical change as a biomarker for Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 20954-9	11.5	173

20	Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. *Schizophrenia Bulletin*, **2009**, 35, 19-31	1.3	258
19	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. *Brain*, **2009**, 132, 1355-65	11.2	831
18	P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. *European Neuropsychopharmacology*, **2009**, 19, S316	1.2	11
17	Bypassing Shame and Conversion Disorder. *European Psychiatry*, **2009**, 24, 1-1	6	
16	Magnetic resonance imaging of liver lesions: exceptions and atypical lesions. *Current Problems in Diagnostic Radiology*, **2008**, 37, 95-103	1.6	8
15	Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. *British Journal of Psychiatry*, **2007**, 191, 355-6	5.4	54
14	Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. *American Journal of Psychiatry*, **2006**, 163, 790-9	11.9	423
13	Do schizophrenia patients want to be involved in their treatment?. *American Journal of Psychiatry*, **2006**, 163, 937; author reply 937	11.9	
12	The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. *Schizophrenia Research*, **2003**, 61, 19-30	3.6	123
11	Plasma catecholamine metabolites in antidepressant-exacerbated mania and psychosis. *Journal of Affective Disorders*, **2002**, 68, 331-4	6.6	10
10	Treatment histories of patients with a syndrome putatively prodromal to schizophrenia. *Psychiatric Services*, **2002**, 53, 342-4	3.3	32
9	MRI monitoring of tumor response to a novel VEGF tyrosine kinase inhibitor in an experimental breast cancer model. *Academic Radiology*, **2002**, 9 Suppl 2, S519-20	4.3	16
8	Antidepressant-associated mania and psychosis resulting in psychiatric admissions. *Journal of Clinical Psychiatry*, **2001**, 62, 30-3	4.6	215
7	Lamotrigine as prophylaxis against steroid-induced mania. *Journal of Clinical Psychiatry*, **1999**, 60, 708-9	4.6	17
6	Premature polypsychopharmacology. *Journal of the American Academy of Child and Adolescent Psychiatry*, **1998**, 37, 348-9	7.2	2
5	Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium		1
4	The spatial chronnectome reveals a dynamic interplay between functional segregation and integration		2
3	Multi-spatial scale dynamic interactions between functional sources reveal sex-specific changes in schizophrenia. *Network Neuroscience*,1-48	5.6	2

2	Multi-Spatial Scale Dynamic Interactions between Functional Sources Reveal Sex-Specific Changes in Schizophrenia		4
1	Path Analysis: A Method to Estimate Altered Pathways in Time-varying Graphs of Neuroimaging Data. *Network Neuroscience*,1-45	5.6	0